Tonix Pharmaceuticals Announces Oral Presentation and Three Poster Presentations at the 2024 Military Health System Research Symposium ( MHSRS ) - Tonix Pharmaceuticals ( NASDAQ:TNXP )

4 weeks ago

Oral presentation highlights TNX-102 SL ( sublingual cyclobenzaprine HCl ) treatment in Phase 3 RESILIENT study demonstrating statistically significant improvement in fibromyalgia nociplastic pain and in all six key secondary endpoints, including sleep quality

Ticker	Sentiment	Impact
TNXP	Neutral	13 %